Contributions
Abstract: EP1657
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Percentage of brain volume change (PBVC) has been suggested as a potential marker of MS disease progression, however, no clear relationship between PBVC and disease free status was clearly described yet. The objective of the study was to evaluate the relationship of PBVC and disease free status in MS patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up.
Methods: RRMS patients, with less than three years from disease onset, EDSS ≤3 and in which IFN beta 1-a 44 mcg was indicated were included. MR scans were acquired 3 to 6 months after the initiation of IFN beta 1-a treatment and every 12 months after during 3 years. Demographic, clinical and structural parameters from the MR scan, during the 3 years of follow up were analyzed and compared between patients with disease free status and no disease free status patients. Disease free status was defined as the absence of a) three month confirmed disability progression defined as an increase in EDSS score of 1.0; b) confirmed relapses; c) new/enlarged T2 lesions. PBVC from baseline to months 12, 12 to 24, 24 to 36 was compared between groups.
Results: 87 patients, mean age 33 ± 6 years, 57 (65.5%) women were included. The mean EDSS of the population was 2.1±0.5, follow up time 40 ± 4.3 months. Disease free status was reached by 31 patients at year 3. PBVC from baseline to months 24 in disease free status patients was -1.1 % vs. -1.54 % in no disease free status patients (p< 0.001) and from baseline to month 36 it was -1.43% vs. -2.1%
(p< 0.001) in disease free and no disease free status respectively.
Conclusion: At 3 years follow up, patients who received IFN beta 1a and were disease free had lower PBVC compared to patients with disease activity.
Disclosure: This research was partially supported by Merck S.A. (Argentina), an affiliate of Merck KGaA, Darmstadt, Germany.
Abstract: EP1657
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Percentage of brain volume change (PBVC) has been suggested as a potential marker of MS disease progression, however, no clear relationship between PBVC and disease free status was clearly described yet. The objective of the study was to evaluate the relationship of PBVC and disease free status in MS patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up.
Methods: RRMS patients, with less than three years from disease onset, EDSS ≤3 and in which IFN beta 1-a 44 mcg was indicated were included. MR scans were acquired 3 to 6 months after the initiation of IFN beta 1-a treatment and every 12 months after during 3 years. Demographic, clinical and structural parameters from the MR scan, during the 3 years of follow up were analyzed and compared between patients with disease free status and no disease free status patients. Disease free status was defined as the absence of a) three month confirmed disability progression defined as an increase in EDSS score of 1.0; b) confirmed relapses; c) new/enlarged T2 lesions. PBVC from baseline to months 12, 12 to 24, 24 to 36 was compared between groups.
Results: 87 patients, mean age 33 ± 6 years, 57 (65.5%) women were included. The mean EDSS of the population was 2.1±0.5, follow up time 40 ± 4.3 months. Disease free status was reached by 31 patients at year 3. PBVC from baseline to months 24 in disease free status patients was -1.1 % vs. -1.54 % in no disease free status patients (p< 0.001) and from baseline to month 36 it was -1.43% vs. -2.1%
(p< 0.001) in disease free and no disease free status respectively.
Conclusion: At 3 years follow up, patients who received IFN beta 1a and were disease free had lower PBVC compared to patients with disease activity.
Disclosure: This research was partially supported by Merck S.A. (Argentina), an affiliate of Merck KGaA, Darmstadt, Germany.